2seventy bio, Inc. (NASDAQ:TSVT) Holdings Lifted by Eversept Partners LP

Eversept Partners LP boosted its stake in 2seventy bio, Inc. (NASDAQ:TSVT) by 0.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,003,678 shares of the company’s stock after buying an additional 5,599 shares during the quarter. Eversept Partners LP’s holdings in 2seventy bio were worth $2,951,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of TSVT. Rhumbline Advisers grew its holdings in shares of 2seventy bio by 9.5% during the 4th quarter. Rhumbline Advisers now owns 84,670 shares of the company’s stock worth $249,000 after purchasing an additional 7,379 shares in the last quarter. Geode Capital Management LLC boosted its position in 2seventy bio by 1.1% during the third quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after purchasing an additional 13,144 shares during the last quarter. State Street Corp lifted its position in shares of 2seventy bio by 1.5% in the third quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after buying an additional 15,638 shares during the last quarter. American Century Companies Inc. grew its holdings in 2seventy bio by 6.6% in the 4th quarter. American Century Companies Inc. now owns 93,552 shares of the company’s stock valued at $275,000 after buying an additional 5,785 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in 2seventy bio by 3.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 428,660 shares of the company’s stock worth $1,260,000 after acquiring an additional 15,061 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TSVT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 2seventy bio in a research note on Tuesday, April 8th. Morgan Stanley decreased their target price on 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Friday, March 14th. Leerink Partners reissued a “market perform” rating and issued a $5.00 price target (down previously from $9.00) on shares of 2seventy bio in a research report on Tuesday, March 11th. Finally, Leerink Partnrs cut shares of 2seventy bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, 2seventy bio presently has a consensus rating of “Hold” and an average price target of $5.60.

2seventy bio Trading Up 0.2 %

TSVT opened at $4.99 on Tuesday. The firm has a market cap of $261.17 million, a price-to-earnings ratio of -2.68 and a beta of 1.04. 2seventy bio, Inc. has a 12 month low of $2.29 and a 12 month high of $5.30. The stock has a fifty day moving average price of $4.11 and a 200-day moving average price of $3.75.

2seventy bio (NASDAQ:TSVT) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.08). 2seventy bio had a negative return on equity of 53.65% and a negative net margin of 207.25%. The firm had revenue of $2.93 million for the quarter, compared to analysts’ expectations of $12.84 million. On average, equities research analysts forecast that 2seventy bio, Inc. will post -1.46 EPS for the current year.

Insider Activity at 2seventy bio

In related news, CEO William D. Baird III sold 5,092 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $4.95, for a total transaction of $25,205.40. Following the transaction, the chief executive officer now owns 1,121,034 shares of the company’s stock, valued at approximately $5,549,118.30. This represents a 0.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $4.93, for a total transaction of $25,350,607.23. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,152,093 shares of company stock worth $25,400,018. Corporate insiders own 7.20% of the company’s stock.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.